Advertisement

Digestive Diseases and Sciences

, Volume 64, Issue 4, pp 928–933 | Cite as

Emerging Role of the Pathologist in Precision Medicine for HCC

  • Thomas LongerichEmail author
  • Peter Schirmacher
Review

Notes

Compliance with ethical standards

Conflict of interest

The author declares that they have no conflict of interest.

References

  1. 1.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRefGoogle Scholar
  2. 2.
    Heimbach J, Kulik LM, Finn R, et al. Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017;67:358–380.CrossRefGoogle Scholar
  3. 3.
    Hayashi PH, Trotter JF, Forman L, et al. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadaveric liver allocation in the era of MELD. Liver Transpl. 2004;10:42–48.CrossRefGoogle Scholar
  4. 4.
    Joo I, Lee JM, Lee SM, Lee JS, Park JY, Han JK. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2016;44:1330–1338.CrossRefGoogle Scholar
  5. 5.
    Mueller C, Waldburger N, Stampfl U, et al. Non-invasive diagnosis of hepatocellular carcinoma revisited. Gut. 2017;67:991–993.CrossRefGoogle Scholar
  6. 6.
    Mullhaupt B, Durand F, Roskams T, Dutkowski P, Heim M. Is tumor biopsy necessary? Liver Transpl. 2011;17:S14–S25.CrossRefGoogle Scholar
  7. 7.
    Caturelli E, Solmi L, Anti M, et al. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut. 2004;53:1356–1362.CrossRefGoogle Scholar
  8. 8.
    Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. Hepatology. 1998;28:323–331.CrossRefGoogle Scholar
  9. 9.
    Torbenson M, Schirmacher P. Liver cancer biopsy–back to the future? Hepatology. 2015;61:431–433.CrossRefGoogle Scholar
  10. 10.
    Maturen KE, Nghiem HV, Marrero JA, et al. Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique. AJR Am J Roentgenol. 2006;187:1184–1187.CrossRefGoogle Scholar
  11. 11.
    Bosman F, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2010:1–417.Google Scholar
  12. 12.
    Saldarriaga J, Bisig B, Couchy G, et al. Focal beta-catenin mutation identified on formalin-fixed and paraffin-embedded inflammatory hepatocellular adenomas. Histopathology. 2017;71:989–993.CrossRefGoogle Scholar
  13. 13.
    Bioulac-Sage P, Sempoux C, Balabaud C. Hepatocellular adenoma: classification, variants and clinical relevance. Semin Diagn Pathol. 2017;34:112–125.CrossRefGoogle Scholar
  14. 14.
    Roncalli M, Roz E, Coggi G, et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology. 1999;30:1174–1178.CrossRefGoogle Scholar
  15. 15.
    International Consensus Group for Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49:658–664.CrossRefGoogle Scholar
  16. 16.
    Theise ND, Curado MP, Franceschi S, et al. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2010:205–216.Google Scholar
  17. 17.
    Pilati C, Letouze E, Nault JC, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25:428–441.CrossRefGoogle Scholar
  18. 18.
    Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67:727–738.CrossRefGoogle Scholar
  19. 19.
    Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410–416.CrossRefGoogle Scholar
  20. 20.
    Minguez B, Hoshida Y, Villanueva A, et al. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol. 2011;55:1325–1331.CrossRefGoogle Scholar
  21. 21.
    Nault JC, De Reynies A, Villanueva A, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145:176–187.CrossRefGoogle Scholar
  22. 22.
    Pellegrino R, Calvisi DF, Neumann O, et al. EEF1A2 inactivates p53 by way of PI3 K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology. 2014;59:1886–1899.CrossRefGoogle Scholar
  23. 23.
    Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169:1327–1341.CrossRefGoogle Scholar
  24. 24.
    Graham RP, Jin L, Knutson DL, et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Mod Pathol. 2015;28:822–829.CrossRefGoogle Scholar
  25. 25.
    Wood LD, Heaphy CM, Daniel HD, et al. Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Mod Pathol. 2013;26:1586–1593.CrossRefGoogle Scholar
  26. 26.
    Li T, Fan J, Qin LX, et al. Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol. 2011;18:1955–1963.CrossRefGoogle Scholar
  27. 27.
    Torbenson MS. Morphologic subtypes of hepatocellular carcinoma. Gastroenterol Clin N Am. 2017;46:365–391.CrossRefGoogle Scholar
  28. 28.
    Nishi H, Taguchi K, Asayama Y, et al. Sarcomatous hepatocellular carcinoma: a special reference to ordinary hepatocellular carcinoma. J Gastroenterol Hepatol. 2003;18:415–423.CrossRefGoogle Scholar
  29. 29.
    Matsuura S, Aishima S, Taguchi K, et al. ‘Scirrhous’ type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1. Histopathology. 2005;47:382–390.CrossRefGoogle Scholar
  30. 30.
    Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol. 2010;34:1630–1636.Google Scholar
  31. 31.
    European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.CrossRefGoogle Scholar
  32. 32.
    Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18:2290–2300.CrossRefGoogle Scholar
  33. 33.
    Horwitz E, Stein I, Andreozzi M, et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov. 2014;4:730–743.CrossRefGoogle Scholar
  34. 34.
    Rudalska R, Dauch D, Longerich T, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med. 2014;20:1138–1146.CrossRefGoogle Scholar
  35. 35.
    El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502.CrossRefGoogle Scholar
  36. 36.
    Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–952.CrossRefGoogle Scholar
  37. 37.
    Zhu AX, Baron AD, Malfertheiner P, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of reach trial results by child-pugh score. JAMA Oncol. 2016;3:235–243.CrossRefGoogle Scholar
  38. 38.
    Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173.CrossRefGoogle Scholar
  39. 39.
    Leichsenring J, Volckmar AL, Kirchner M, et al. Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility. Genes Chromosomes Cancer. 2018;57:70–79.CrossRefGoogle Scholar
  40. 40.
    Allgauer M, Budczies J, Christopoulos P, et al. Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. Transl Lung Cancer Res. 2018;7:703–715.CrossRefGoogle Scholar
  41. 41.
    Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62:1420–1429.CrossRefGoogle Scholar
  42. 42.
    Brunner SM, Itzel T, Rubner C, et al. Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. Oncotarget. 2017;8:71002–71011.CrossRefGoogle Scholar
  43. 43.
    Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169:1342–1356.CrossRefGoogle Scholar
  44. 44.
    Bodenmiller B. Multiplexed epitope-based tissue imaging for discovery and healthcare applications. Cell Syst. 2016;2:225–238.CrossRefGoogle Scholar
  45. 45.
    Campbell BB, Light N, Fabrizio D, et al. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171:1042–1056.CrossRefGoogle Scholar
  46. 46.
    Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500–2501.CrossRefGoogle Scholar
  47. 47.
    Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of PathologyUniversity Hospital HeidelbergHeidelbergGermany

Personalised recommendations